Pharmafile Logo

News and Press Releases

EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years

Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX compared to DES Significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with...

Category: Biotechnology, Clinical Trials, Other
Posted: May 21, 2025

Elixir Medical
info@elixirmedical.com
920 N. McCarthy Blvd. Milpitas, CA 95035 U.S.

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Rybelsus reduced major adverse cardiovascular events by 14% vs placebo in adults with type 2 diabetes and cardiovascular and/or chronic kidney disease in the SOUL cardiovascular outcomes trial Data were...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 29, 2025

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25

Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...

Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025

Cleerly
info@cleerlyhealth.com
1099 18th St #2860, Denver, CO 80202

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

Venus Remedies gets Marketing Authorization for anticoagulant ‘Enoxaparin’ from Indonesia

Latest approvals from Indonesia, Southeast Asia’s largest pharma market, to help strengthen company’s regional and global aspirations 10 February 2025 -- Panchkula, India -- Venus Remedies Limited, a leading Indian exporter...

Category: Drug Delivery, Other, Pharmaceutical
Posted: February 10, 2025

Venus Remedies
info@venusremedies.com, bd@venusremedies.com
51-52, Industrial Area Phase-1, Panchkula, Haryana, 134113

BioTrinity 2025, 1-2 April, Convene, 133 Houndsditch, London

About BioTrinity: BioTrinity, now in its 19th year, is OBN's flagship two-day conference for the life sciences industry, designed to catalyse growth for all who attend. The two-day conference programme for 2025...

Category: BioManufacturing
Posted: February 6, 2025

BioFIT
Parc Chanot 114. Rond-Point du Prado 13008 Marseille FRANCE

Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference

26 March 2024 -- California, US -- Shockwave Medical, a pioneer in the development and commercialisation of transformational technologies for the treatment of cardiovascular disease, announced today that the company...

Category: Biotechnology
Posted: March 26, 2024

Shockwave Medical
media@shockwavemedical.com
5403 Betsy Ross Drive Santa Clara, CA, 95054 - USA

Novo Nordisk to acquire Cardior Pharmaceuticals and strengthenpipeline in cardiovascular disease

25 March, 2024 -- Bagsværd, Denmark, and Hannover, Germany -- Novo Nordisk and CardiorPharmaceuticals today announced that Novo Nordisk has agreed to acquire Cardior for up to€1.025bn, including an upfront...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 26, 2024

Novo Nordisk
abmo@novonordisk.com
Novo Nordisk A/S Novo Allé, 2880 Bagsvaerd Denmark

Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session

25 March 2024 -- California, US -- Cytokinetics today announced four presentations at the American College of Cardiology 73rd Annual Scientific Session (ACC.24) taking place in Atlanta, Georgia, US, from 6-8 April 2024. Title: 1075-11 - Efficacy and...

Category: Drug Discovery, Pharmaceutical
Posted: March 25, 2024

Cytokinetics
media@cytokinetics.com
350 Oyster Point Blvd South San Francisco, CA 94080